PHAT – phathom pharmaceuticals, inc. (US:NASDAQ)
Stock Stats
News
Phathom Pharmaceuticals, Inc. (NASDAQ: PHAT) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $26.00 price target on the stock.
Phathom Pharmaceuticals, Inc. (NASDAQ: PHAT) is now covered by analysts at Stifel Nicolaus. They set a "buy" rating and a $24.00 price target on the stock.
Phathom Pharmaceuticals to Report First Quarter 2024 Financial Results and Provide Business Update on Thursday, May 9, 2024
Phathom Pharmaceuticals, Inc. (NASDAQ: PHAT) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $26.00 price target on the stock.
SynOx Therapeutics announces $75m Series B round to fund Phase 3 trial of potential best-in-class treatment for TGCT
Form DEFA14A Phathom Pharmaceuticals,
Form DEF 14A Phathom Pharmaceuticals, For: May 23
Form ARS Phathom Pharmaceuticals, For: Dec 31
Form 4 Phathom Pharmaceuticals, For: Apr 08 Filed by: Henderson Molly
Form SC 13D/A Phathom Pharmaceuticals, Filed by: TAKEDA PHARMACEUTICAL CO LTD
Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies
If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.